AUROPHARMA.NS Cash Flow
Aurobindo Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹2,386.75 Cr. | ₹2,434.52 Cr. | ₹3,924.62 Cr. | ₹5,526.37 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-3,977.75 Cr. | ₹-4,255.95 Cr. | ₹-1,875.14 Cr. | ₹-3,458.43 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹1,814.41 Cr. | ₹800.42 Cr. | ₹119.78 Cr. | ₹-1,269.15 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹-0.06 Cr. | ₹14.17 Cr. | ₹9.10 Cr. | ₹828.82 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹223.35 Cr. | ₹-1,006.84 Cr. | ₹2,178.36 Cr. | ₹1,627.61 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹4,168.92 Cr. | ₹4,392.27 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from AUROPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).